Home Therapeutic relationship Inotrem and the Crohn’s & Colitis Foundation sign an R&D collaboration agreement to support the development of a new therapeutic approach in inflammatory bowel disease (IBD)

Inotrem and the Crohn’s & Colitis Foundation sign an R&D collaboration agreement to support the development of a new therapeutic approach in inflammatory bowel disease (IBD)


Inotrem will leverage the Foundation’s cohort resources to identify a novel therapeutic target focused on the TREM-1 pathway.

PARIS, April 14, 2022–(BUSINESS WIRE)–Inotrem, a late-stage clinical-stage biotechnology company specializing in immunotherapies for acute and chronic inflammatory syndromes, today announced an R&D collaboration agreement with the Crohn’s & Colitis Foundation to support the development of a new therapeutic approach in IBD. The Crohn’s & Colitis Foundation is one of the world’s largest and most influential nonprofit organizations dedicated to finding cures for Crohn’s disease and ulcerative colitis.

The objective of the R&D collaboration is to confirm the relationship between the activation of the TREM-1 pathway and the severity and progression of IBD in patients, with the ultimate intention of developing a new treatment. Inotrem will lead this project in partnership with the Division of Gastroenterology at the Icahn School of Medicine at Mount Sinai in New York. Under the terms of the agreement, Inotrem will access data and biological specimens from the Foundation’s IBD Plexus®, which is the largest IBD database in the United States with data from more than 25,000 patients. The project is expected to last 18 months and will form the cornerstone of the design of the first-in-human clinical study of Inotrem’s new drug candidate.

Today there are 10 million people worldwide with IBD (Crohn’s disease and ulcerative colitis), a lifelong condition for which the medical need remains high despite improvement over the past 30 years. About 30% of patients are mostly unresponsive to existing therapies and even among responders, up to 10% will lose their response to the drug every year.

For a decade, Inotrem has pioneered the biology of TREM-1 as a regulator of immune response in acute and chronic inflammatory diseases. TREM-1 has been reported as a likely contributor to IBD pathophysiology, and targeting this biological pathway could offer a new treatment option for IBD patients with immune dysregulation.

Sven Zimmermann, CEO of Inotrem, said, “We look forward to working with such a recognized and respected organization as the Crohn’s & Colitis Foundation. The robustness and diversity of their IBD patient database is unprecedented and will allow for in-depth analysis of the potential of TREM-1 as a therapeutic target in patients with IBD. This agreement marks the beginning of a long and fruitful partnership”.

“We are committed to finding cures for Crohn’s disease and ulcerative colitis and improving the quality of life for those affected by these diseases,” said Dr. Caren Heller, chief scientific officer of the Crohn’s & Colitis Foundation. “We are excited to work with Inotrem, a company that has developed strong scientific leadership around the TREM-1 pathway, and we look forward to understanding the potential ways the TREM-1 pathway may play a role in treating disease. inflammation of the intestine. .”

About Inotrem
Inotrem SA is a biotechnology company specializing in the immunotherapy of acute and chronic inflammatory syndromes. The company has developed a novel immunomodulation concept that targets the TREM-1 pathway to control imbalanced inflammatory responses. Using its proprietary technology platform, Inotrem has developed the first TREM-1 inhibitor, LR12 (nangibotide), with potential applications in a number of therapeutic indications such as septic shock and myocardial infarction. In parallel, Inotrem also launched another program to develop a new therapeutic modality targeting chronic inflammatory diseases. The company was founded in 2013 by Dr Jean-Jacques Garaud, former head of research and early development of the Roche group, Pr Sébastien Gibot and Dr Marc Derive. Inotrem is backed by leading European and North American investors. www.inotrem.com

See the source version on businesswire.com: https://www.businesswire.com/news/home/20220413005626/en/


Media contact for Inotrem
Strategies & Image (S&I)
[email protected]
+33 6 03 35 92 05